Document is current
Any future updates will be listed below
-
Authors
Grune, Jana
Lewis, Andrew J. M.
Yamazoe, Masahiro
Hulsmans, Maarten https://orcid.org/0000-0003-1009-658X
Rohde, David https://orcid.org/0000-0002-3785-9375
Xiao, Ling https://orcid.org/0000-0002-5463-5576
Zhang, Shuang
Ott, Christiane https://orcid.org/0000-0002-3199-0655
Calcagno, David M. https://orcid.org/0000-0001-7022-9220
Zhou, Yirong
Timm, Kerstin https://orcid.org/0000-0001-9136-7518
Shanmuganathan, Mayooran https://orcid.org/0000-0001-8036-6253
Pulous, Fadi E. https://orcid.org/0000-0002-0794-8078
Schloss, Maximillian J.
Foy, Brody H.
Capen, Diane
Vinegoni, Claudio https://orcid.org/0000-0002-9818-3639
Wojtkiewicz, Gregory R. https://orcid.org/0000-0002-3148-8411
Iwamoto, Yoshiko
Grune, Tilman
Brown, Dennis
Higgins, John https://orcid.org/0000-0002-9182-0076
Ferreira, Vanessa M.
Herring, Neil https://orcid.org/0000-0001-8453-6133
Channon, Keith M.
Neubauer, Stefan
,
Shanmuganathan, Mayooran
Ferreira, Vanessa M.
Channon, Keith M.
Sosnovik, David E.
Milan, David J.
Swirski, Filip K. https://orcid.org/0000-0002-3163-9152
King, Kevin R.
Aguirre, Aaron D. https://orcid.org/0000-0002-5509-1646
Ellinor, Patrick T. https://orcid.org/0000-0002-2067-0533
Nahrendorf, Matthias https://orcid.org/0000-0002-4021-1887
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R35HL139598)
- License Information
-
More Information
Article History
Received: 15 December 2021
Accepted: 6 June 2022
First Online: 11 July 2022
Competing interests
: J.G. and M.N. filed an invention disclosure on the STORM model. M.N. has received funds or material research support from Alnylam, Biotronik, CSL Behring, GlycoMimetics, GlaxoSmithKline, Medtronic, Novartis and Pfizer as well as consulting fees from Eli Lilly, Biogen, Gimv, IFM Therapeutics, Molecular Imaging, Sigilon and Verseau Therapeutics. P.T.E. has received sponsored research support from Bayer AG and IBM Health and has consulted for Bayer AG, Novartis and MyoKardia. A.D.A. has received sponsored research support from Amgen and Philip Research. The other authors declare no competing interests.
